Matthew J Maurice1, Debasish Sundi2, Edward M Schaeffer3, Robert Abouassaly4. 1. Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio. 2. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 4. Department of Urology, University Hospitals Case Medical Center, Cleveland, Ohio. Electronic address: robert.abouassaly@uhhospitals.org.
Abstract
PURPOSE: The impact of African-American race on oncologic outcomes for low risk prostate cancer is unclear due to conflicting data. We investigated the effect of African-American race on pathological upgrading and/or up staging at prostatectomy in men with clinically low risk prostate cancer. MATERIALS AND METHODS: We queried the National Cancer Database for men with low risk prostate cancer (clinical stage T2a or less, Gleason score 6 or less, prostate specific antigen less than 10 ng/ml) treated with radical prostatectomy between 2010 and 2013. The outcomes were pathological upgrading to Gleason score greater than 6 (primary) or Gleason score greater than 3+4=7 (secondary) and/or up staging (pathological T3-4 or N1 disease). The association between race and the end points was assessed using multivariable logistic regression. To further adjust for potential confounders, stratification by urban residence and comorbidity score, and subgroup analyses were performed. RESULTS: With adjustment for age, comorbidity, income, urban residence, T stage, prostate specific antigen and percentage of positive biopsy cores, African-American race conferred 1.2-fold higher odds of pathological upgrading to Gleason score greater than 6 and/or up staging (OR 1.2, 95% CI 1.1-1.3, p <0.01). African-American race also was an independent predictor of pathological upgrading to Gleason score greater than 3+4=7 and/or up staging (p=0.03). CONCLUSIONS: African-American men with low risk prostate cancer are more likely to harbor higher risk disease, which may lead to adverse outcomes. This finding alone does not preclude active surveillance. However, race should be considered as men weigh the risks and benefits of active surveillance vs treatment.
PURPOSE: The impact of African-American race on oncologic outcomes for low risk prostate cancer is unclear due to conflicting data. We investigated the effect of African-American race on pathological upgrading and/or up staging at prostatectomy in men with clinically low risk prostate cancer. MATERIALS AND METHODS: We queried the National Cancer Database for men with low risk prostate cancer (clinical stage T2a or less, Gleason score 6 or less, prostate specific antigen less than 10 ng/ml) treated with radical prostatectomy between 2010 and 2013. The outcomes were pathological upgrading to Gleason score greater than 6 (primary) or Gleason score greater than 3+4=7 (secondary) and/or up staging (pathological T3-4 or N1 disease). The association between race and the end points was assessed using multivariable logistic regression. To further adjust for potential confounders, stratification by urban residence and comorbidity score, and subgroup analyses were performed. RESULTS: With adjustment for age, comorbidity, income, urban residence, T stage, prostate specific antigen and percentage of positive biopsy cores, African-American race conferred 1.2-fold higher odds of pathological upgrading to Gleason score greater than 6 and/or up staging (OR 1.2, 95% CI 1.1-1.3, p <0.01). African-American race also was an independent predictor of pathological upgrading to Gleason score greater than 3+4=7 and/or up staging (p=0.03). CONCLUSIONS: African-American men with low risk prostate cancer are more likely to harbor higher risk disease, which may lead to adverse outcomes. This finding alone does not preclude active surveillance. However, race should be considered as men weigh the risks and benefits of active surveillance vs treatment.
Authors: H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman Journal: J Urol Date: 2013-05-06 Impact factor: 7.450
Authors: Brandon A Mahal; Ayal A Aizer; David R Ziehr; Andrew S Hyatt; Toni K Choueiri; Jim C Hu; Karen E Hoffman; Christopher J Sweeney; Clair J Beard; Anthony V D'Amico; Neil E Martin; Simon P Kim; Quoc-Dien Trinh; Paul L Nguyen Journal: Clin Genitourin Cancer Date: 2014-05-09 Impact factor: 2.872
Authors: Farzana A Faisal; Debasish Sundi; John L Cooper; Elizabeth B Humphreys; Alan W Partin; Misop Han; Ashley E Ross; Edward M Schaeffer Journal: Urology Date: 2014-12 Impact factor: 2.649
Authors: Debasish Sundi; Farzana A Faisal; Bruce J Trock; Patricia K Landis; Zhaoyong Feng; Ashley E Ross; H Ballentine Carter; Edward M Schaeffer Journal: Urology Date: 2014-10-14 Impact factor: 2.649
Authors: David Schreiber; Arpit Chhabra; Justin Rineer; Jeremy Weedon; David Schwartz Journal: Clin Genitourin Cancer Date: 2015-02-21 Impact factor: 2.872
Authors: Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544
Authors: Maria A Gosein; Dylan Narinesingh; Shastri Motilal; Adrian P Ramkissoon; Cristal M Goetz; Kristy Sadho; Murrie D Mosodeen; Renee Banfield Journal: Radiol Imaging Cancer Date: 2020-07-31
Authors: Helen Y Hougen; Oleksii A Iakymenko; Sanoj Punnen; Chad R Ritch; Bruno Nahar; Dipen J Parekh; Oleksandr N Kryvenko; Mark L Gonzalgo Journal: World J Urol Date: 2022-06-10 Impact factor: 3.661
Authors: Megan Hansen; Nadine M Hamieh; Sarah C Markt; Jane B Vaselkiv; Claire H Pernar; Amparo G Gonzalez-Feliciano; Samuel Peisch; Ilkania M Chowdhury-Paulino; Emily M Rencsok; Timothy R Rebbeck; Elizabeth A Platz; Edward L Giovannucci; Kathryn M Wilson; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.090
Authors: Rishi Deka; P Travis Courtney; J Kellogg Parsons; Tyler J Nelson; Vinit Nalawade; Elaine Luterstein; Daniel R Cherry; Daniel R Simpson; Arno J Mundt; James D Murphy; Anthony V D'Amico; Christopher J Kane; Maria Elena Martinez; Brent S Rose Journal: JAMA Date: 2020-11-03 Impact factor: 56.272
Authors: Jonathan B Bloom; Amir H Lebastchi; Samuel A Gold; Graham R Hale; Thomas Sanford; Sherif Mehralivand; Michael Ahdoot; Kareem N Rayn; Marcin Czarniecki; Clayton Smith; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter L Choyke; Howard L Parnes; Baris Turkbey; Peter A Pinto Journal: BJU Int Date: 2019-06-26 Impact factor: 5.969
Authors: Neel H Patel; Jonathan Bloom; Joel Hillelsohn; Sean Fullerton; Denton Allman; Gerald Matthews; Majid Eshghi; John L Phillips Journal: Health Equity Date: 2018-05-01